Subcutaneous Versus Combined Subcutaneous and Intramuscular Botulinum Toxin for Androgenetic Alopecia: A Randomized Clinical Trial

This randomized clinical trial evaluated the efficacy of botulinum toxin type A as a monotherapy for androgenetic alopecia (AGA) by comparing subcutaneous application to combined subcutaneous and intramuscular application in 15 male patients. Over 6 months, no significant changes were observed in hair density or hair-to-terminal hair ratio in either treatment group. However, a significant reduction in hair thickness in the frontal region was noted in both groups, and a significant decrease in terminal hair count in the frontal region was observed in the combined treatment group. No significant differences were found between the two treatment modalities, and the study concluded that botulinum toxin does not support the treatment of AGA.